Here’s what you should know:
1. The miRpredX 31-3p is the first positive theranostic test for patients with metastatic colorectal cancer.
2. The test will be marketed as a CE-IVD product. The CE mark denotes the product is effective and safe.
3. The test identifies patients who would better respond to anti-EGFR drugs like cetuximab. It also allows physicians to take personalized medicine approaches.
4. IntegraGEn’s Director of Molecular Diagnostics Yann Gaston-Mathe said in a release, “Achieving CE-IVD for the miRpredX 31-3p kit is a significant milestone for IntegraGen after only five years of test development and clinical validation. We anticipate strong interest for this test as a result of the demand by oncologists for better tools to personalize treatment approaches for cancer patients.”
More articles on gastroenterology:
Acquisitions, legislator visits & more: 8 GI practices in the news
8 facts on medical coder salary — median, regional & historical data
GI center to know: East Valley Endoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
